Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30196% above fair value
$11.62+0.72 (+6.61%)
Close on Nov 13, 2026Market cap $407.48MP/E 387.3Yield –
Fennec Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Fennec Pharmaceuticals's enterprise value was $331.51M on Nov 11, 2026, against $207.88M a year earlier. Over the last 5 years it ranged from $76.10M to $391.42M, with a median of $201.23M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $331.51M | +70.8% |
| 2025 | Dec 31, 2025 | $194.13M | +46.0% |
| 2024 | Dec 31, 2024 | $132.99M | -53.6% |
| 2023 | Dec 29, 2023 | $286.45M | +15.9% |
| 2022 | Dec 30, 2022 | $247.13M | +174.3% |
| 2021 | Dec 31, 2021 | $90.10M | -43.4% |
| 2020 | Dec 31, 2020 | $159.12M | +39.7% |
| 2019 | Dec 31, 2019 | $113.89M | +20.8% |
| 2018 | Dec 31, 2018 | $94.27M | -36.8% |
| 2017 | Dec 29, 2017 | $149.20M | – |
| 2016 | Dec 30, 2016 | -$4.51M | – |
See a number that looks wrong?